

# Voyageur Pharmaceuticals Ltd. Announces Issuance of Shares for Debt

written by Raj Shah | January 27, 2023

January 27, 2023 ([Source](#)) – Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the “Company” or “Voyageur”) announces that, further to its news release dated December 2, 2022, it has issued a total of 125,322 Common Shares at a deemed price of \$0.09974 per Common Share for payment of outstanding debts of \$12,500 owed to former directors of the Company and the outstanding debts have now been extinguished.

The Common Shares issued by the Company have a hold period of four months and one day from the date of issuance in accordance with applicable securities legislation.

## About Voyageur

Voyageur is a Canadian public company listed on the TSXV under the trading symbol VM. Voyageur is focused on the development of barium and iodine Active Pharmaceutical Ingredients (“API”) and high-performance cost-effective imaging contrast agents for the medical imaging marketplace. Voyageur’s goal is to fully integrate the barium and iodine contrast market by producing its own minerals of barium and iodine. The business plan is to initially generate cash flow from operations using third party GMP pharmaceutical manufacturers in Canada and validate the products for regulatory agencies globally. Then transitioning into a high margin domestic manufacturer of radiology drugs. Voyageur has plans to build carbon neutral infrastructure to become 100% self-sufficient across all manufacturing activities. Voyageur owns a 100% interest in three barium sulphate (barite)

projects including the Frances Creek property, suitable in grade for the pharmaceutical marketplace, with additional interests in a high-grade iodine, lithium & bromine brine project located in Utah, USA. Voyageur is moving forward with its business plan of becoming the only fully integrated carbon neutral company in the radiology contrast media drug market, by controlling all primary input costs under the motto of:

**“From the Earth to the Bottle”.**

***For Further Media Information or to set up an interview, please contact:***

***Brent Willis***

***President & CEO***

***E [brent@vpharma.ca](mailto:brent@vpharma.ca)***

***[www.voyageurpharmaceuticals.ca](http://www.voyageurpharmaceuticals.ca)***

***Al Deslauriers***

***CFO***

***E [albert@vpharma.ca](mailto:albert@vpharma.ca)***

**NOT FOR RELEASE IN THE UNITED STATES OF AMERICA**

This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States. Any securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “1933 Act”) and may not be offered or sold in the United States or to or for the account or benefit of a U.S. person in the absence of such registration or an exemption from the registration requirements of the 1933 Act and applicable U.S. state securities laws.

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.*